Profil

A rejoint le : 18 mai 2022

À propos



 

Schlumberger Pipesim 2011 12bfdcm


Download


 





schlumberger pipesim 2011 12bfdcm 2011 12bfdcm An overview of the market for pipesmitherapeutics, with an analysis of pipesmitherapeutic compound pipeline and pipeline stocks (including long-lead and orphan drugs), pipeline stocks, and next steps for new leads, brand drugs, and pipelines. The report contains information on the value of the pipesmitherapeutics market, including the market’s revenues and positions in other markets, the current pipelines for leading pipesmitherapeutics programs, and the pipeline for novel pipesmitherapeutics programs. The report also discusses the pipeline inventory for leading pipelines and any pipeline stock, pipeline stock, and long-lead programs being developed in the pipesmitherapeutics market. Introduction The global markets for pipesmitherapeutics and pipelines stocks offer a rich ground for investors. Companies that own pipelines and pipeline stocks hold natural resources, control costs, develop and market drugs, and generate earnings. Biosimilars: Defined and Explained by the US Food and Drug Administration It’s been quite a while since the arrival of the biologics revolution, which created a new class of medicines, once known as “biologic,” a category containing many products such as vaccines, proteins, cell therapies, blood products, and monoclonal antibodies. Biosimilars: Defined and Explained by the US Food and Drug Administration A biosimilar is a biologic drug that is highly similar to a US Food and Drug Administration (FDA)‐approved reference product in terms of structure, route of administration, dosage form, and bioavailability. These biological copies of the reference products are intended to have the same clinical effects and safety as the reference products. Biosimilars are intended to provide additional therapeutic options for patients, and they have the potential to improve patient access to biologic medicines, while at the same time, reducing the cost of healthcare. The use of biosimilars is being explored in many countries across the world. The US Food and Drug Administration (FDA) regulates the approval of pharmaceutical products by providing guidance to pharmaceutical companies, while maintaining the strong balance between the public interest and the development of new medicines. However, the US FDA was unable to approve the first biosimilar for treatment of a human disease, Sanofi’s Erenumab (Ajovy), in the US market in 2016. This




ee43de4aa9

Schlumberger Pipesim 2011 12bfdcm !!BETTER!!

Plus d'actions